Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

This study is testing everolimus combined with a chemotherapy drug of the doctor's choice as a first treatment for a specific subtype of triple-negative breast cancer (TNBC) that is LAR (luminal androgen receptor) positive and has mutations in the PAM pathway. Triple-negative breast cancer does not respond to hormone therapy, and this subtype may respond to drugs that target different growth pathways. **You may be eligible if...** - You are 18 to 70 years old with confirmed triple-negative, LAR subtype breast cancer with PAM pathway mutations - Your cancer is recurrent or metastatic and cannot be fully removed with surgery - You have not previously received chemotherapy or targeted therapy for advanced disease - Your overall health (ECOG 0-1) and organ function are adequate - You have at least one measurable or evaluable lesion **You may NOT be eligible if...** - Your cancer has spread to the brain or you have a history of brain metastases - You have significant uncontrolled heart disease - You are pregnant or breastfeeding - You have active hepatitis B or C infection - You have had another cancer in the past 5 years (with some exceptions) Talk to your doctor to see if this trial is right for you.